DK1773757T3 - TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf - Google Patents

TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf

Info

Publication number
DK1773757T3
DK1773757T3 DK05770295.3T DK05770295T DK1773757T3 DK 1773757 T3 DK1773757 T3 DK 1773757T3 DK 05770295 T DK05770295 T DK 05770295T DK 1773757 T3 DK1773757 T3 DK 1773757T3
Authority
DK
Denmark
Prior art keywords
sub
applications
formulations containing
trpv1 agonists
hydrogen
Prior art date
Application number
DK05770295.3T
Other languages
English (en)
Inventor
Giovanni Appendino
Paolo Morazzoni
Antonella Riva
Gabriele Fontana
Marzo Vincenzo Di
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Application granted granted Critical
Publication of DK1773757T3 publication Critical patent/DK1773757T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C07C303/46—Separation; Purification from by-products of refining mineral oils with sulfuric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05770295.3T 2004-07-30 2005-07-06 TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf DK1773757T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001566A ITMI20041566A1 (it) 2004-07-30 2004-07-30 "trpv1 agonisti, formulazioni che li contengono e loro usi"
PCT/EP2005/007292 WO2006010445A1 (en) 2004-07-30 2005-07-06 Trpv1 agonists, formulations containing them and uses thereof

Publications (1)

Publication Number Publication Date
DK1773757T3 true DK1773757T3 (da) 2011-11-21

Family

ID=34979120

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05770295.3T DK1773757T3 (da) 2004-07-30 2005-07-06 TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf

Country Status (19)

Country Link
US (1) US7429673B2 (da)
EP (1) EP1773757B1 (da)
JP (1) JP4819810B2 (da)
KR (1) KR101206571B1 (da)
CN (1) CN101006047B (da)
AT (1) ATE524433T1 (da)
AU (1) AU2005266684B2 (da)
CA (1) CA2575341C (da)
DK (1) DK1773757T3 (da)
ES (1) ES2370029T3 (da)
HK (1) HK1105947A1 (da)
IL (1) IL181024A (da)
IT (1) ITMI20041566A1 (da)
NO (1) NO338341B1 (da)
PL (1) PL1773757T3 (da)
PT (1) PT1773757E (da)
RU (1) RU2379282C2 (da)
SI (1) SI1773757T1 (da)
WO (1) WO2006010445A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
KR101034300B1 (ko) * 2008-12-02 2011-05-16 고려대학교 산학협력단 Ｔｒｐｖ３ 활성 억제 약물 및 이의 활용
KR101034299B1 (ko) * 2008-12-02 2011-05-16 고려대학교 산학협력단 Ｔｒｐｖ３ 활성 조절 약물 및 이의 활용
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011006073A1 (en) 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US10327467B2 (en) 2010-04-14 2019-06-25 Altria Client Services Llc Preformed smokeless tobacco product
EP2629610B1 (en) 2010-07-27 2017-09-06 Flex Pharma, Inc. Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US10799548B2 (en) * 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
AU2016301282B2 (en) 2015-08-03 2022-03-17 Children's Medical Center Corporation Charged ion channel blockers and methods for use
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
EP3937945A4 (en) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MA55320A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation
JP2022527690A (ja) 2019-03-11 2022-06-03 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2023517604A (ja) 2020-03-11 2023-04-26 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493848A (en) 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
FR2619810B1 (fr) * 1987-09-02 1990-01-05 Hoechst France Nouveaux monomeres ethyleniques polyfonctionnels
IT1302264B1 (it) * 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
JP2004182674A (ja) * 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物

Also Published As

Publication number Publication date
CN101006047B (zh) 2010-08-11
NO338341B1 (no) 2016-08-08
CN101006047A (zh) 2007-07-25
KR101206571B1 (ko) 2012-11-29
ATE524433T1 (de) 2011-09-15
RU2379282C2 (ru) 2010-01-20
JP2008508202A (ja) 2008-03-21
HK1105947A1 (en) 2008-02-29
WO2006010445A1 (en) 2006-02-02
RU2007103344A (ru) 2008-08-10
EP1773757B1 (en) 2011-09-14
CA2575341C (en) 2014-09-23
KR20070039078A (ko) 2007-04-11
AU2005266684A1 (en) 2006-02-02
EP1773757A1 (en) 2007-04-18
AU2005266684B2 (en) 2012-05-10
IL181024A0 (en) 2007-07-04
PL1773757T3 (pl) 2012-02-29
PT1773757E (pt) 2011-10-27
CA2575341A1 (en) 2006-02-02
ITMI20041566A1 (it) 2004-10-30
SI1773757T1 (sl) 2011-12-30
IL181024A (en) 2011-12-29
ES2370029T3 (es) 2011-12-12
US7429673B2 (en) 2008-09-30
NO20070531L (no) 2007-04-30
JP4819810B2 (ja) 2011-11-24
US20080132573A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
DK1773757T3 (da) TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
TW200612920A (en) Novel imidazolidine derivatives
DK1899325T3 (da) Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase
UA84208C2 (en) Tetraazabenzo(e)azulene derivatives and analogs thereof
NO20075809L (no) DNA-PK inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
MA31763B1 (fr) Inhibiteurs de kinase de type polo
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
MX2010000658A (es) Derivados de pirimidina 934.
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
SE0302139D0 (sv) Novel compounds
MY183326A (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
SE0200919D0 (sv) Chemical compounds
SE0403085D0 (sv) Novel componds
MXPA06000936A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
SE0303280D0 (sv) Novel compounds
GB0512284D0 (en) Organic compounds
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
SE0403117D0 (sv) New compounds 1